TruScreen Group Limited Share Price

Current Share Price data for TruScreen Group Limited (NZX:TRU ASX:TRU)

NZX Listing
ASX Listing
Investing in TruScreen is an opportunity to invest in the future health and wellbeing of women around the world.

Cervical cancer can and should be prevented.

TruScreen provides an accurate, real-time primary screening solution. 
Our screening solution is ideal for communities that can’t access conventional laboratory-based screening methods. It is affordable and easy to learn.

Our purpose is to ensure that all women of screening age – no matter who or where they are – have access to quality screening.

TruScreen manufactures and owns all rights to the TruScreen Cervical Cancer Screening System. The system comprises a medical device and AI-enabled process designed to detect, in real-time, the presence of pre-cancerous and cancerous tissue on the cervix.

TruScreen’s focus markets are low and-middle income countries (LMICs) where there is a lack of organised cervical cancer screening and the required infrastructure.

Find out more about the company

Stock Research Reports

Pitt Street Research
7.3.2023

Detecting Cervical Cancer

TruScreen Group Ltd (NZX/ASX: TRU) is a medtech company that is commercialising the TRU system.

Pitt Street Research
20.11.2020

Truly promising growth ahead

TruScreen Group Ltd (NZX: TRU) provides an opto-electrical technology-based real-time, low cost and portable system for the detection of cancer or pre-cancerous cells in cervical tissues.

TruScreen Latest NZX & ASX Announcements

GENERAL
13.3.2023

Outstanding Clinical Evaluation Results from Saudi Arabia

Truscreen Group Limited is pleased to advise that the leading private medical services provider , Dr. Sulaiman Al-Habib Medical Group, has recently completed the analysis of results from its cervical screening clinical evaluation of TruScreen Ultra and Liquid Based Cytology (LBC).

GENERAL
8.3.2023

China Ramps Up for Public Health Check Centres

Truscreen Group Limited is pleased to advise that its China distributor has placed an order for 40 TruScreen cervical cancer screening devices for installation into China’s growing public Health Check Sector. Delivery is expected in April 2023.

OFFER
3.3.2023

TruScreen Raises $600,000 in Initial Share Placement

Truscreen Group Limited is pleased to advise that further to the announcement of 17 February 2023 “Truscreen to lodge a pro rata renounceable rights issue”, the Company has received firm commitments from a number of investors for an initial Placement of 20,000,000 shares at NZ$0.03 each to raise $600,000, before costs.

OFFER
28.2.2023

TruScreen Rights Issue Offer Opens

Truscreen Group Limited announced its intention to launch a 1 for 5 pro-rata renounceable rights issue to raise up to circa $2.2 million ("Rights Offer”) on 17 February 2023.

OFFER
24.2.2023

Rights Issue Offer Document

Further to the announcement on 17 February 2023 in relation to a Pro Rata Renounceable Rights Issue, TruScreen is pleased to provide the Offer Document, attached to this announcement.

OFFER
17.2.2023

Cleansing Notice

Notice of Offer of Same Class Financial Products for Issue. Truscreen Group Limited intends to undertake an offer of new ordinary shares in TRU by way of a pro-rata 1 for 5 renounceable rights offer to eligible shareholders followed by an Oversubscription Bookbuild Facility process.

OFFER
17.2.2023

TruScreen Corporate Action Notice

A Corporate Action Notice relating to a Pro Rata Renounceable Rights Issue is attached.

OFFER
17.2.2023

TruScreen to Lodge a Pro Rata Renounceable Rights Issue

TruScreen Group Limited is pleased to announce its intention to launch a one (1) for five (5) pro-rata renounceable rights issue to raise up to circa NZD$2.2 million ("Rights Offer”).

GENERAL
15.2.2023

February Commercial Update

Cervical cancer screening technology company, TruScreen Group Limited (NZX/ASX: TRU) (‘TruScreen’ or ‘the Company), is pleased to provide this commercial update.

GENERAL
19.12.2022

Distributor Update December 2022

Cervical cancer screening technology company, TruScreen Group Limited (NZX/ASX: TRU) (‘TruScreen’ or ‘the Company), is pleased to provide this update on Distributor progress in November/ December 2022.

HALFYR

TruScreen Half Year Results Template (NZX)

Template Results announcement - for Equity Security issuer/Equity and Debt Security issuer

HALFYR

TruScreen Group Limited Interim Report September 2022

HALFYR

TruScreen Half Year Results

Cervical cancer screening technology company, TruScreen Group Limited (NZX/ASX: TRU) (‘TruScreen’ or ‘the Company), is pleased to provide its unaudited financial results for the six months to 30 September 2022 (1H FY23), along with the following operational update. TruScreen reports according to the New Zealand financial year, which runs from 1 April to 31 March.

GENERAL

TruScreen Market Update

Cervical cancer screening technology company, TruScreen Group Limited (NZX/ASX: TRU), is pleased to provide this market update which includes commentary on its unaudited financial results for the six months to 30 September 2022 (1H FY23).

GENERAL
9.11.2022

TruScreen Stakeholder Newsletter November 2022

Truscreen Limited is pleased to provide a copy of its November 2022 Stakeholders Newsletter. This gives an updated on TruScreen's performance and highlights key initiatives underway.

GENERAL
2.11.2022

Hosts Global Medical Symposium, Expands Reach in Vietnam

Truscreen Group Limited (NZX/ASX:TRU) is pleased to announce successful completion of the first global virtual medical symposium to key opinion leaders from 7 countries, on cervical cancer screening.

GENERAL
6.10.2022

Dr Beata Edling Appointed CEO of TruScreen Group

Truscreen Group Limited (NZX/ASX:TRU) is pleased to announce the appointment of Dr. Beata Edling as Chief Executive Officer.

GENERAL
1.9.2022

TRU Signs Five Year Manufacturing Agreement for SUS Supply

TruScreen Group Limited (NZX/ASX: TRU) is pleased to announce that it has executed a five-year manufacturing contract with its current critical supplier, Zapco International Limited, for the manufacture and supply of Single Use Sensors.

GENERAL
10.8.2022

Relaunch of TruScreen Devices in Xinjiang Uygur Region

TruScreen Group Limited (NZX/ASX: TRU) is pleased to announce that its China distributor Beijing Siweixiangtai Technology Company Ltd (SWXT) has relaunched distribution of TruScreen cervical cancer screening device to Xinjiang Uygur Autonomous Region.

GENERAL
3.8.2022

TruScreen Cervical Cancer Screening Centre Mexico City

TruScreen Group Limited (NZX/ASX: TRU) is pleased to announce the establishment of a TruScreen-based cervical cancer screening centre in a new clinic in Cludad de Mexico (Mexico City) operated by leading healthcare provider Mexpharm Medical Clinical.

GENERAL
5.4.2022

COGA Trial Validates Superiority of Truscreen

COGA Trial screened 15,661 women across 64 hospitals in 9 provinces over 3 years. TruScreen specificity surpassed Liquid Based Cytology (LBC) and hrHPV. TruScreen was determined to be a simple, effective and rapid real-time cervical cancer screening method

GENERAL
3.3.2022

TruScreen Achieves Significant Milestones with Distributors

TruScreen Group Limited (NZX/ASX: TRU) (‘TruScreen’ or ‘the Company’) is pleased to provide the following market update, outlining the Company’s progress.

TruScreen Group Limited Announcements

TruScreen Group is dual-listed on the NZX and ASX.  All of our announcements are available through our website, or via the NZX and ASX platforms.

View announcements

Meet the Team

TruScreen has a wealth of experienced, highly skilled professionals across its Directors, Executive Team, Medical Advisory Board, and Research & Development Team.

 

TruScreen Team